Gilead Lowers 2016 Net Product Sales Forecast, Shares Fall


Gilead Sciences Inc. cut its product sales forecast for 2016 and reported lower-than-expected sales in the second quarter for its hepatitis C drugs, sending the shares lower in late trading. Net product sales will be $29.5 billion to $30.5 billion for the year, down from a previous forecast of $30 billion to $31 billion, Foster City, California-based Gilead said Monday in a statement.



from Biotech News